Filing Flows › Gyre Therapeutics (GYRE) › Q2 2025
Gyre Therapeutics (GYRE) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 11, 2025
Gyre Therapeutics (GYRE) reported revenue of $26.8M for the second quarter 2025 (Q2 2025), +6% from a year earlier and +21% from the quarter before. Operating margin was 8.1%, net earnings $1.6M (5.9% of revenue).
Gyre Therapeutics, Q2 2025: revenue $26.8M (+6% year over year), operating margin 8.1%, net earnings $1.6M, operating cash flow $2.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26.8M | +21% | +6% |
| Gross profit | $25.6M | +21% | +5% |
| Operating profit | $2.2M | -4% | -32% |
| Net earnings | $1.6M | -58% | -65% |
| Operating cash flow | $2.1M | — | — |
| Free cash flow | $1.8M | — | — |
What changed
Revenue was $26.8M in Q2 2025, up 6% year over year and up 21% from the previous quarter.
Gross margin was 95.7%, down 1.2 points from a year earlier. Operating profit was $2.2M, a 8.1% margin (down 4.6 points year over year). Operating profit fell $1.0M even though revenue rose $1.5M versus a year earlier, so costs grew faster than sales. Operating expenses grew 10% against revenue growth of 6%. The fastest-growing cost line was Other operating costs (+18649%). Net earnings were $1.6M, down 65% year over year. The effective tax rate was 29.6%.
Operating cash flow was $2.1M, 132% of net earnings. Non-cash charges added back $641K of depreciation and amortization and $906K of share-based compensation. Working capital and other items used $1.0M. Capital expenditures of $256K left free cash flow of $1.8M.
Questions
What was Gyre Therapeutics' revenue in the second quarter 2025?
Gyre Therapeutics (GYRE) reported revenue of $26.8M for the second quarter 2025 (Q2 2025), +6% from a year earlier and +21% from the quarter before.
Was Gyre Therapeutics profitable in the second quarter 2025?
Operating profit was $2.2M (8.1% of revenue) and net earnings $1.6M.
Source: Gyre Therapeutics 10-Q on SEC EDGAR.